Related references
Note: Only part of the references are listed.FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia
Claire E. Curtis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N. Boissel et al.
LEUKEMIA (2006)
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia
J Score et al.
LEUKEMIA (2006)
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway
Piotr Smolewski
ANTI-CANCER DRUGS (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines
D Watanabe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia
AM Safley et al.
GENES CHROMOSOMES & CANCER (2004)
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia
MA Morgan et al.
LEUKEMIA (2003)
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
RS Care et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Necessity of tyrosine 719 and phosphatidylinositol 3′-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation
K Hashimoto et al.
BLOOD (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Famesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
JE Lancet et al.
BLOOD (2003)
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
K Spiekermann et al.
BLOOD (2002)
Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor β receptor
PM Irusta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene
MK Magnusson et al.
BLOOD (2002)
Tyrosine kinase fusion genes in chronic myeloproliferative diseases
NCP Cross et al.
LEUKEMIA (2002)
JAKs, STATs and Src kinases in hematopoiesis
SG Rane et al.
ONCOGENE (2002)
The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways
DW Sternberg et al.
BLOOD (2001)
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
RJ Chian et al.
BLOOD (2001)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity
ZQ Ning et al.
ONCOGENE (2001)
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2001)
Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells
ZQ Ning et al.
BLOOD (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Development of anticancer drugs targeting the MAP kinase pathway
JS Sebolt-Leopold
ONCOGENE (2000)
TEL/PDGFβR fusion protein activates STAT1 and STAT5:: A common mechanism for transformation by tyrosine kinase fusion proteins
AM Wilbanks et al.
EXPERIMENTAL HEMATOLOGY (2000)
Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses
H Kissel et al.
EMBO JOURNAL (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility
P Blume-Jensen et al.
NATURE GENETICS (2000)
Share Paper
